Intraabdominal infections, with their high morbidity and mortality, represent an immense treatment challenge because multiple microorganisms are involved. The addition of cefepime to metronidazole has been shown to be effective but the cost of the drug is high. Therefore, the objective of this study was to assess the cost-effectiveness of this combination compared to cefotaxime-metronidazole from the perspective of the thirdparty payer. METHODS: Data were obtained on the resources consumed by 60 adults with intraabdominal infection enrolled in a randomized trial carried out in the Intensive Care Unit, Hospital of Specialties "La Raza", Mexico City comparing cefepime to cefotaxime, both in addition to metronidazole. Clinical cure, improvement or failure, was determined according to presence of symptoms while bacteriological cure depended on absence of the initial microorganisms. For the economic study, data on length of stay (LOS); use of special care units, laboratory tests, radiology, nuclear medicine or other special studies; number and type of surgeries as well as duration of antimicrobial treatment were collected. Information was extracted from patient charts and case report forms. Unit costs were obtained from the hospital's Finance Department and are reported in 2001 US dollars (1 USD = 10 MEX). RESULTS: There were no statistically significant differences between groups in age, gender, number and type of diagnoses or severity of disease. Staphylococcus aureus, Streptococcus spp, Escherichia coli, Enterococcus spp and Pseudomona aeuruginosa were most frequently isolated. There were no statistically significant differences in the number and type of tests. Clinical and bacteriologic efficacy were similar between groups. However, patients receiving cefepimemetronidazole had shorter LOS than patients receiving cefotaxime-metronidazole (mean 21 days versus 27 days, respectively) and thus lower total hospitalization costs (mean $18,974 for cefepime-metronidazole vs. $20,092 for cefotaxime-metronidazole). Including the cost of the drugs, the difference is reduced to $503 in favor of cefepime-metronidazole. CONCLUSIONS: The combination of cefepime with metronidazole reduces average total costs resulting in economic dominance over cefotaxime.
OBJECTIVE:
Three studies presented at the XIV International AIDS conference in Barcelona, Spain give support to the discontinuation of secondary prophylaxis (SP) of cryptocycoccal meningitis (CM), mycobacterium avium (MAC), and disseminated histoplamosis (DH) after immunological reconstitution with HAART. Our objective was to estimate potential cost savings of withdrawing secondary prophylaxis. METHODS: Three separate analyses were performed, one for each opportunistic infection (OI) analyzed and were each comprised of 100 HIV-infected patients who were assumed to be naïve for antiretroviral therapy and previously diagnosed with one of the given OI's. As in the prophylaxis studies, we assumed that all patients were receiving HAART and secondary prophylaxis for six months. Clinical outcomes following six months were taken from the prophylaxis studies and previously published HAART studies. HAART and SP drug costs (2002 U.S. AWP) from the payer perspective were determined for the period following 6 months of HAART treatment through the duration of each given prophylaxis-study time frame (11 months for CM, 12 months for MAC, and 16 months for DH). The number of patients in the cohort who could potentially discontinue SP was calculated as was their perpatient costs. Similar estimations were made for patients who could not discontinue (including HAART nonresponders). Discounting was not performed due to the short analytical timeframe. RESULTS: In the CM cohort, 42 patients discontinued SP at a monthly cost of $1052.31 per patient versus $1449.61 for the remaining 76 patients not discontinuing (27.4% savings per discontinuation). In the MAC cohort, 24 patients discontinued SP at a cost of $1052.31 per patient versus $1463.57 for the remainder (28.1% savings), and $1052.31 per patient in the DH cohort where all patients discontinued (30.7% savings). CONCLUSION: Given that discontinue secondary prophylaxis is considered safe after immunological reconstitution with HAART, the potential cost savings can be substantial.
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Increasing awareness of the utmost need for the limited resources to be used more efficiently has called for eco-
